vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
14.03
-0.46 (-3.17%)
Aug 13, 2025, 4:00 PM - Market closed
vTv Therapeutics Employees
vTv Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 7 or 43.75% compared to the previous year.
Employees
23
Change (1Y)
7
Growth (1Y)
43.75%
Revenue / Employee
$739
Profits / Employee
-$850,217
Market Cap
100.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VTVT News
- 1 day ago - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 days ago - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewsWire
- 7 days ago - vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - GlobeNewsWire
- 2 months ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 3 months ago - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire